MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal
Synopsis
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.
Day One Biopharmaceuticals, Inc. (DAWN) said on Thursday that it has signed a definitive merger agreement to acquire Mersana Therapeutics (MRSN) for up to $285 million.
Day One will commence a tender offer to acquire all of the outstanding shares of Mersana common stock for $25 per share in cash at closing, in addition to a contingent value right (CVR) that allows holders to receive up to an aggregate of $30.25 per CVR upon the completion of certain milestones.
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. The transaction is expected to close by the end of January 2026.
MRSN shares traded 206% higher in the pre-market session at the time of writing.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.